The impact of preapheresis white blood cell count on autologous peripheral blood stem cell collection efficiency and HSC infusion side effect rate

2018 ◽  
Vol 33 (3) ◽  
pp. 331-341 ◽  
Author(s):  
Araci. M. Sakashita ◽  
Andrea T. Kondo ◽  
Ana Paula H. Yokoyama ◽  
Sanny M. C. Lira ◽  
Carolina B. Bub ◽  
...  
Keyword(s):  
Stem Cell ◽  
Blood Cell ◽  
Cell Count ◽  
Peripheral Blood ◽  
Side Effect ◽  
Peripheral Blood Stem Cell ◽  
Collection Efficiency ◽  
Blood Cell Count ◽  
The Impact ◽  
Stem Cell Collection

scholarly journals Study of Peripheral Mononuclear Cells and CD34 Levels as a Predictive Marker for Initiating Apheresis in Autologous Stem Cell Transplant

2021 ◽  
Author(s):  
Kiran PK ◽  
Vinu Sarathy P ◽  
Srinivas BJ ◽  
Girish V Badarkhe ◽  
Rajesh Kumar KS ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Stem Cell ◽  
Cell Count ◽  
Hodgkin Lymphoma ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Optimal Time ◽  
Cell Transplant ◽  
Stem Cell Collection

Background: Autologous HCT in multiple myeloma is done as upfront treatment in newly diagnosed transplant eligible patients after induction chemotherapy. In addition, it is standard for relapsed, aggressive non-Hodgkin lymphoma (NHL) and classical Hodgkin lymphoma (HL), and is curative in ~40% to 45% of patients. Over a decade, many efforts were made to find helpful parameters to predict an optimal time for initiating an efficient peripheral blood stem cell collection so that adequate stem cells are collected.  It has been well accepted that CD34+ cell count in peripheral blood before leukapheresis is the best parameter to predict CD34 cell yield. However, white blood cell count, mononuclear cell count, and other easily obtained parameters are still used to guide the clinical practice of peripheral blood stem cell mobilization and collection.  Materials and Methods: In the present study, we analyzed the correlation between peripheral blood MNC and Apheresis CD34 levels and also between peripheral blood CD34 by flow cytometry and apheresis CD34 levels. Results: We found that there was a statistically insignificant weak correlation between peripheral MNC and apheresis CD34. There was a statistically significant strong correlation between peripheral CD34 and apheresis CD34. Conclusion: The results show that peripheral blood MNC was analogous indicating that no reliable prediction can be done for CD34 cells collected in apheresis while peripheral CD34 by flow cytometry is the strongest predictor for initiating stem cell collection.

Evaluation of Two Different Protocols for Peripheral Blood Stem Cell Collection with the Fresenius AS 104 Blood Cell Separator

Vox Sanguinis ◽  
1997 ◽  
Vol 73 (4) ◽  
pp. 230-236
Author(s):  
Bruno Bizzi ◽  
Giacomo Menichella ◽  
Marco Lai ◽  
Luca Pierelli ◽  
Mariangela Vittori ◽  
...  
Keyword(s):  
Stem Cell ◽  
Blood Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Cell Separator ◽  
Blood Cell Separator ◽  
Stem Cell Collection

Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 1925-1925
Author(s):  
Nelson J. Chao ◽  
Lisa M Bernard ◽  
George Carrum ◽  
Henry C. Fung ◽  
Daniel T Grima ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Peripheral Blood ◽  
Research Funding ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Advisory Committees ◽  
Cell Counts ◽  
Collection Practices ◽  
Stem Cell Collection

Abstract Abstract 1925 After mobilization, the timing of aphaeresis can be highly variable, often depending on rise in peripheral blood stem cell levels. Some centers that conduct autologous stem cell transplant (ASCT) do not conduct aphaeresis for stem cell collection on weekends. We examined stem cell collection practices and related outcomes in centers that do and do not conduct weekend aphaeresis. Methods: A retrospective, multi-center chart review was conducted of multiple myeloma (MM) and lymphoma patients mobilized between January 1, 2006 and December 31, 2007 for ASCT. Patients were excluded if they were mobilized with plerixafor (Mozobil®) or were enrolled in a clinical trial of mobilization regimens. Data collected included demographics, disease and treatment history, mobilization regimen, blood counts, aphaeresis, remobilization, cells transplanted, time to engraftment, and resource use. Stem cell collection practices and related clinical outcomes were analyzed separately for sites that did and did not conduct weekend aphaeresis. Results: Data were collected for 292 consecutive patients in the different centers (91 patients from 4 sites that performed weekday only aphaeresis and 201 patients from 7 sites who performed aphaeresis on weekends and weekdays). Weekday only aphaeresis sites were more likely to conduct GCSF alone mobilization compared to weekend sites (42% vs. 21%, p<0.005). Approximately half the patients at each site had MM. The day of the week that aphaeresis was initiated differed dramatically between groups with 74% of chemo-mobilization patients starting aphaeresis on a Monday in the weekday only group compared to 26% in the other group. Approximately 15% of chemo-mobilization patients started aphaeresis on a weekend in the group that conducted weekend aphaeresis. No chemo-mobilization patients began aphaeresis on a Friday in the weekday only aphaeresis group compared to 11% in the other group. Sixteen of all aphaeresis procedures occurred on the weekend on the sites that conducted weekend aphaeresis. Significant differences were found between weekend and weekday only sites, with regards to total cells collected (16.01 × 106/kg vs. 9.2 × 106/kg, p<0.05) and cells collected on day one of aphaeresis (10.8 × 106/kg vs 5.5 × 106/kg, p<0.05) for chemo-mobilization patients. Use of peripheral blood stem cell counts differed markedly, with counts conducted on the first day of aphaeresis in 18% of weekday only group patients and 61% of weekend group patients. Discussion: Significant differences in the management of patients were observed between sites that conduct and don't conduct weekend aphaeresis. Weekday only aphaeresis sites used a more regimented collection schedule with most collections starting on a Monday, potentially missing the “peak” day of cell collection. Sites that conducted weekend aphaeresis used a more cell-count based approach and were more likely to monitor peripheral blood stem cell counts. Collection success appears to be superior with the cell-count based approach that includes greater use of chemo-mobilization, cell count monitoring and weekend collection. Disclosures: Chao: Genzyme: Research Funding. Bernard:Cornerstone Research: Employment, Equity Ownership. Fung:Genzyme: Consultancy, Honoraria, Speakers Bureau. Grima:Cornerstone Research Group Inc.: Employment, Equity Ownership. Holmberg:Genzyme: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millenium: Research Funding; Otsuka: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Celgene: Research Funding. Brown:Cornerstone Research: Employment. Horwitz:Genzyme: Honoraria, Research Funding. Shaughnessy:Genzyme: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millenium: Honoraria, Speakers Bureau; Otsuka: Honoraria, Speakers Bureau. Tricot:Otsuka: I have an ongoing clinical study supported by Otsuka.

scholarly journals Factors affecting autologous peripheral blood hematopoietic stem cell collections by large-volume leukapheresis: a single center experience

2011 ◽  
Vol 9 (2) ◽  
pp. 196-200 ◽  
Author(s):  
Araci Massami Sakashita ◽  
Andrea Tiemi Kondo ◽  
Andreza Alice Feitosa Ribeiro ◽  
Andrea Neri Folchini Cipolletta ◽  
Monica Vilela Colesanti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Cell Yield ◽  
Hematopoietic Stem ◽  
Factors Affecting ◽  
Peripheral Blood Cd34 ◽  
Stem Cell Collection

Objective: To evaluate factors affecting peripheral blood hematopoietic stem cell yield in patients undergoing large-volume leukapheresis for autologous peripheral blood stem cell collection. Methods: Data from 304 consecutive autologous peripheral blood stem cell donors mobilized with hematopoietic growth factor (usually G-CSF), associated or not with chemotherapy, at Hospital Israelita Albert Einstein between February 1999 and June 2010 were retrospectively analyzed. The objective was to obtain at least 2 × 106 CD34+ cells/kg of body weight. Pre-mobilization factors analyzed included patient's age, gender and diagnosis. Post mobilization parameters evaluated were pre-apheresis peripheral white blood cell count, immature circulating cell count, mononuclear cell count, peripheral blood CD34+ cell count, platelet count, and hemoglobin level. The effect of pre and post-mobilization factors on hematopoietic stem cell collection yield was investigated using logistic regression analysis (univariate and multivariate approaches). Results: Pre-mobilization factors correlating to poor CD34 + cell yield in univariate analysis were acute myeloid leukemia (p = 0.017) and other hematological diseases (p = 0.023). Significant post-mobilization factors included peripheral blood immature circulating cells (p = 0.001), granulocytes (p = 0.002), hemoglobin level (p = 0.016), and CD34+ cell concentration (p < 0.001) in the first harvesting day. However, according to multivariate analysis, peripheral blood CD34+ cell content (p < 0.001) was the only independent factor that significantly correlated to poor hematopoietic stem cell yield. Conclusion: In this study, peripheral blood CD34+ cell concentration was the only factor significantly correlated to yield in patients submitted to for autologous collection.

Evaluation of Two Different Protocols for Peripheral Blood Stem Cell Collection with the Fresenius AS 104 Blood Cell Separator

Vox Sanguinis ◽  
1997 ◽  
Vol 73 (4) ◽  
pp. 230-236 ◽  
Author(s):  
Giacomo Menichella ◽  
Marco Lai ◽  
Luca Pierelli ◽  
Mariangela Vittori ◽  
Riccardo Serafini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Blood Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Cell Separator ◽  
Blood Cell Separator ◽  
Stem Cell Collection

CD34+ collection efficiency as a function of blood volumes processed in pediatric autologous peripheral blood stem cell collection

2011 ◽  
Vol 26 (3) ◽  
pp. 131-137 ◽  
Author(s):  
Leonid Dubrovsky ◽  
Edward C.C. Wong ◽  
Evelio Perez-Albuerne ◽  
Brett Loechelt ◽  
Naynesh Kamani ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Collection Efficiency ◽  
Blood Stem Cell ◽  
Stem Cell Collection ◽  
Blood Volumes

High Correlation of Pre-Apheresis Peripheral Blood CD34+ Cell Counts with Final Apheresis Product CD34+ Cell Count by Using a More Accurate Determination of Patient Blood Volume

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2996-2996
Author(s):  
Brandon Parker ◽  
James Hastings ◽  
Jill Folkert ◽  
Gayla Nagy ◽  
Carlos Bachier ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Blood Volume ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Accurate Determination ◽  
Blood Stem Cell ◽  
Cell Counts ◽  
The Mean ◽  
Stem Cell Collection

Abstract Abstract 2996 The final apheresis product CD34+ cell count per Kg of recipient weight is used to determine if additional apheresis procedures are necessary to collect the targeted amount of hematopoietic stem cells for autologous peripheral blood stem cell transplantation. Flow cytometric analysis of CD34+ cells can take several hours. A more timely technique to predict apheresis product CD34+ cell counts during apheresis may help determine if further administration of cytokines is necessary or if apheresis catheters can be removed, and overall improve the efficiency of patient (pt) care. We performed a retrospective review of all pts undergoing autologous peripheral blood stem cell mobilization with granulocyte-colony stimulating factor (G-CSF) alone, G-CSF and plerixafor, or with chemotherapy followed by G-CSF, from July 2010 through May 2011 who underwent peripheral blood stem cell collection with apheresis on the COBE Spectra cell separator. Linear regression models were used to formulate the calculation of pt blood volume based on the pre-apheresis CD34+ cell count per micro liter of blood, the final apheresis product CD34+ cell counts, and the amount of blood processed during the apheresis procedure. This calculated blood volume is expressed by the formula BV = 82.5(patients weight in Kg) + 793. We then prospectively evaluated the next consecutive pts who underwent stem cell mobilization and apheresis in June and July 2011. Twenty-seven apheresis collections were done on 26 pts. Fourteen pts were female, and 12 pts were male. Seventeen pts were diagnosed with myeloma, 6 pts with NHL, and 3 pts with other diseases. Twenty pts were mobilized with G-CSF (10 ug/kg daily) with apheresis to begin on day 5. Fifteen of the 20 pts required plerixafor on day 4 because of low peripheral blood CD34+ cell counts (< 10/ul). Six pts were mobilized with chemotherapy followed by G-CSF 10 ug/kg daily until peripheral CD34 cell counts recovered greater than 10/ul and then apheresis was started. Each pt had their blood volume calculated according to the formula above and the peripheral blood CD 34+ cell count was measured on the first and second day of apheresis. The peripheral blood CD 34+ cell count/ul was multiplied by 1000 and this product was multiplied by the calculated blood volume and then divided by the pts weight [(PBCD34+ cell count × 1000) × BV]/Kg to determine the predicted apheresis product CD34+ cell count, which was then compared to the actual apheresis product final CD34+ cell count. On the first day of collection the mean for the predicted product CD34+ cell count was 4.98 × 106 +/− 3.1 × 106, and the actual apheresis product CD34+ cell count was 4.61 × 106 +/− 2.90 × 106 (Pearson correlation r value of 0.913 and a p value <0.001)(see figure). Nineteen collections were evaluable on the second day of collection with the mean for the predicted product CD34 + cell count of 2.08 × 106 +/− 1.64 × 106, and the mean for the actual apheresis product CD34+ cell count of 2.29 × 106 +/− 0.768 × 106 (Pearson correlation r value of 0.620 with a p value of 0.005). There was no significant difference in the correlation between patients mobilized with G-CSF alone, G-CSF and plerixafor or after chemotherapy and G-CSF. In conclusion, a more accurate determination of patient blood volume allowed for a high degree of correlation on the first day of peripheral blood stem cell collection on the COBE Spectra machine between the predicted product CD34+ cell count and the actual apheresis product CD34+ cell count. An accurate prediction of the final apheresis product CD34+ cell count may allow for less cytokine administration, quicker removal of apheresis catheters, and more efficient disposition of patients undergoing peripheral blood stem cell collection. Disclosures: Shaughnessy: Otsuka: Honoraria, Speakers Bureau; Millenium: Honoraria, Speakers Bureau; Genzyme: Consultancy, Honoraria, Research Funding, Speakers Bureau.

Sign in / Sign up

Export Citation Format

Share Document